Search results
Results from the WOW.Com Content Network
German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements, the U ...
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
By 2008 Glenmark was the fifth-biggest pharmaceutical company in India. [5] By 2011 the founder of the company was one of the richest men in India, [6] and Glenmark had worldwide sales of $778 million, a 37% increase over the last year's sales; the growth was driven by Glenmark's entry into the US and European generics markets. [7]
To do this, complete the exclusion form available on the settlement website or send an email. You also have until Oct. 31 to object to the settlement if you disagree with the terms. r/94_ny ...
Non-DvP settlement processes typically expose the parties to settlement risk. They are known by a variety of names, including free delivery, free of payment or FOP [3] delivery, or in the United States, delivery versus free. [4] FOP settlement involves delivery of the securities without a simultaneous transfer of funds – hence 'free of payment'.
On Monday, Ligand Pharmaceuticals (NAS: LGND) confirmed that Merck (NYS: MRK) will pay it a $2 million milestone payment, as the latter begins phase 2b/3 clinical trials of a new cancer drug.
down to how much each company is willing to pay for a physician’s business, which is often being simultaneously solicited by multiple competing companies. Kickbacks offered to physicians by medical device manufacturers take a variety of forms, ranging from free practice management services to all-expense-paid trips and sham consulting agreements.
Reverse payment patent settlements, also known as "pay-for-delay" agreements, [1] are a type of agreement that has been used to settle pharmaceutical patent infringement litigation (or threatened litigation), in which the company that has brought the suit agrees to pay the company it sued. That is, the patent holder pays the alleged infringer ...